Skip to content

A Sibling Oocyte Study- Comparison of ZyMotTM Microfluidics Device to Density Gradient for Sperm Selection During ICSI

A Sibling Oocyte Study- Comparison of ZyMotTM Microfluidics Device to Density Gradient for Sperm Selection During ICSI

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04818593
Enrollment
108
Registered
2021-03-26
Start date
2021-06-18
Completion date
2021-11-29
Last updated
2023-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ART

Keywords

ICSI

Brief summary

The primary objective of this study is to evaluate whether the percentage of good quality embryo formation following Intracytoplasmic Sperm Injection (ICSI) is improved with the use of ZyMot method of microfluidic sperm separation compared to density gradient.

Detailed description

During an in vitro fertilization (IVF) cycle, eggs are removed from a woman's ovaries via a minor surgical procedure and are inseminated with sperm in order to create embryos. The insemination process can be via standard IVF or intracytoplasmic sperm injection (ICSI.) Standard IVF is the process of placing thousands of sperm in a culture dish with one or more eggs and allowing them to interact on their own. ICSI is the process by which one sperm is directly injected into each egg. Prior to using the sperm for insemination, a semen sample is processed and washed in order to obtain the healthiest sperm. A standard sperm preparation procedure is density gradient, in which the sperm is spun via centrifugation and separated from the seminal fluid. An alternate method is via microfluidics, by which the sperm swim up a microfluidic gradient created by a microporous filter between two chambers of a device. Sperm that are capable of navigating through this filter and reaching the end chamber are presumed to be the healthiest sperm. There is some data revealing that ZyMot microfluidics yields healthier sperm compared to the density gradient technique. The aim of the study is to evaluate whether good quality embryo formation is any different following insemination with sperm separated by microfluidics compared to density gradient. On the day of oocyte retrieval, the sperm sample will be split between the two different processing methods: density gradient and ZyMot microfluidics. In the event that there are 6 or more mature oocytes and ICSI will be used for insemination, half of the oocytes will be inseminated with sperm processed by density gradient and half with sperm processed by ZyMot microfluidics. The percentage of good quality embryo formation will be compared between the two groups.

Interventions

DEVICEZyMot Multi Sperm Separation Device (850 ul)

850 uL of untreated semen will be directly deposited into the inlet port of the ZyMotTM Multi device, followed by placement of 750 uL culture medium in the outlet port and throughout the upper collection chamber. The device will then be incubated in a humidified 37C CO2 incubator for 30 minutes. During incubation, the healthiest and most motile sperm will swim through the microporous filter and into the upper collection chamber, where they will be recovered via the outlet port. 500 uL of the sperm sample will be removed and placed in a separate tube for analysis and insemination.

Density gradient centrifugation will be performed using a one-layer preparation of 90% Isolate in 15 mL conical tubes. Semen will be layered over 1 mL of gradient and then centrifuged for 15 min at 300xg. The supernatant will be removed and discarded. The sperm pellet will be washed by mixing with Multipurpose Handling Medium Complete and centrifuging the sample for 5 min at 400xg. After the wash, the supernatant is removed and discarded and the pellet is re-suspended in culture medium, assessed for sperm parameters, and held at room temperature until insemination.

Sponsors

NYU Langone Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

for Patients: 1. Patient(s) over 18 years of age 2. Patient(s) capable of providing informed consent 3. Use or possible use of ICSI for oocyte insemination 4. At least 6 mature oocytes at time of insemination via ICSI

Exclusion criteria

for Patients: 1. Patient under 18 y/o 2. Patients not capable of providing informed consent 3. Use of IVF for insemination 4. Less than 6 mature oocytes at time of rertrieval 5. Anonymous donor sperm source 6. Surgically retrieved sperm 7. Sperm sample not sufficient for use with ZyMot device Inclusion Criteria for Donors: 1. Donor(s) over 18 years of age 2. Donor(s) capable of providing informed consent 3. Use of ejaculate sperm, fresh or frozen, for insemination 4. Sufficient sperm for use of ZyMot

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Good Quality Blastocyst FormationCulture Day 5 or 6Good quality embryos will be defined as blastocyst stage embryos on day 5 or 6 of culture with an overall quality grade of good or fair. Embryo morphology assessment includes two parts: an Overall Grade and the Stage. Grading is a subjective assessment of the overall quality of the embryo as good, fair, or poor, and is based on assessment of certain characteristics of the embryo, such as fragmentation, symmetry, inner cell mass (ICM) quality and trophectoderm quality. The percentage will be reported for both arms (ZyMot compared to density gradient).

Countries

United States

Participant flow

Pre-assignment details

The trial enrolled 108 unique individuals grouped into 54 patient/sperm-source dyads. Each enrolled dyad produced oocyte units. Oocytes from the same dyad were assigned to the density gradient (control) arm, ZyMot (treatment) arm, or both depending on the criteria met by the oocyte units, meaning the same 54 dyads were assigned to both study arms. Dyads who produced insufficient samples for ZyMot processing were withdrawn.

Participants by arm

ArmCount
Study Population
Individuals in patient/sperm-source dyads with oocyte units that were analyzed.
66
Total66

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyConversion to IUI due to low response11
Overall StudyLow Oocyte Yield88
Overall StudyNot ICSI Insemination77
Overall StudyPoor Sperm Quality22
Overall StudyWithdrawal by Subject22

Baseline characteristics

CharacteristicStudy Population
Age, Continuous36.9 years
STANDARD_DEVIATION 0.6
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
65 Participants
Sex: Female, Male
Female
33 Participants
Sex: Female, Male
Male
33 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 330 / 33
other
Total, other adverse events
0 / 330 / 33
serious
Total, serious adverse events
0 / 330 / 33

Outcome results

Primary

Percentage of Good Quality Blastocyst Formation

Good quality embryos will be defined as blastocyst stage embryos on day 5 or 6 of culture with an overall quality grade of good or fair. Embryo morphology assessment includes two parts: an Overall Grade and the Stage. Grading is a subjective assessment of the overall quality of the embryo as good, fair, or poor, and is based on assessment of certain characteristics of the embryo, such as fragmentation, symmetry, inner cell mass (ICM) quality and trophectoderm quality. The percentage will be reported for both arms (ZyMot compared to density gradient).

Time frame: Culture Day 5 or 6

Population: Participants refer to dyads. Information form one of the completed dyads was not collected.

ArmMeasureValue (MEAN)Dispersion
ZyMot SeparationPercentage of Good Quality Blastocyst Formation51.4 percentage of embryosStandard Deviation 5.1
Density Gradient CentrifugationPercentage of Good Quality Blastocyst Formation51.7 percentage of embryosStandard Deviation 5.4

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026